Summary of Mirum Pharmaceuticals Conference Call Company Overview - **Company**: Mirum Pharmaceuticals (NasdaqGM:MIRM) - **Event**: 2026 Conference on March 11, 2026 Key Points Financial Guidance and Commercial Strategy - Mirum Pharmaceuticals reiterated its revenue guidance for 2026, projecting between **$630 million and $650 million** [4] - The company is focused on funding R&D programs while maintaining durable trends in commercial performance [4] Upcoming Data Events - Key data events scheduled for Q2 2026 include: - **VISTAS PSC** top-line data, pivotal for potential NDA filing by year-end [4] - **Brelovitug** Phase 2b interim readout from the AZURE-1 study [5] - **EXPAND** top-line readout in Q4 2026 [5] EXPAND Program - The EXPAND program targets ultra-rare cholestasis conditions, with a significant portion of patients expected to be pediatric [7][9] - The potential market for LIVMARLI is projected to reach **at least $1 billion**, with EXPAND contributing approximately one-third of that [9] Geographic Expansion - LIVMARLI is currently available in **low- to mid-30 countries**, with most international sales driven by Alagille syndrome [11] - Opportunities for growth exist in regions like the Middle East and Latin America, where sales have been limited [11] Adult PFIC Market - The adult PFIC market is still in early stages, with increased genetic testing among providers expected to drive growth [12] - The company anticipates continued patient diagnosis and treatment persistence, contributing to long-term growth [13] PSC and PBC Opportunities - Approximately **60%** of diagnosed PSC patients are reported to experience meaningful itch, indicating a significant market for antipruritic therapies [19] - The company plans to conduct market development work to raise awareness of pruritus among healthcare professionals and patients [20] Launch Timeline - Following the release of top-line results, Mirum plans to engage with the FDA for pre-submission interactions, aiming for an NDA filing in the second half of 2026 and potential approval in 2027 [24] - Significant revenue contributions from new products are expected to begin in **2028** [25] Brelovitug Market Development - The company is focused on shifting testing paradigms for hepatitis delta, with a goal to increase diagnosis rates through reflex testing [30][32] - The estimated diagnosed and insured population for delta is around **15,000**, with a full prevalence of approximately **40,000** [33] Competitive Positioning - Brelovitug is positioned as a highly active regimen with a strong safety profile, focusing on endpoints linked to improved patient outcomes [37] - The company anticipates a **$750 million** floor guidance for brelovitug, based on conservative assumptions regarding market penetration [39] Future Growth and Business Development - Mirum remains active in seeking new rare disease programs, maintaining a high bar for potential acquisitions to ensure financial strength [47][48] Additional Insights - The company emphasizes the importance of patient experience and education in driving treatment uptake and market growth [18][21] - Mirum's strategy includes leveraging existing teams and distributor networks to expand market access, particularly in regions with lower GDP [44]

Mirum Pharmaceuticals Conference Call Summary Company Overview - **Company**: Mirum Pharmaceuticals (NasdaqGM:MIRM) - **Focus**: Rare disease medicines, with a strategy centered on developing high-impact therapies for patients with rare diseases [4][5] Financial Performance - **Revenue Guidance**: Expected top line revenue for 2026 is between $630 million and $650 million, reflecting strong performance across three approved medicines [5][29] - **Growth Drivers**: The company anticipates four pivotal readouts over the next 18 months, indicating a pivotal year for growth [5][46] Product Pipeline and Commercial Opportunities LIVMARLI - **Indications**: Approved for Alagille syndrome and PFIC, with ongoing expansion into additional indications through the EXPAND study [8][30] - **Mechanism**: LIVMARLI reduces circulating bile acid levels, significantly alleviating symptoms such as pruritus in patients [8][9] - **Market Dynamics**: Steady growth in Alagille syndrome patient starts; PFIC adoption is dynamic due to increased genetic testing [10][13] - **Sales Growth**: LIVMARLI sales are expected to contribute significantly to the overall revenue, with projections indicating it could become a billion-dollar brand [45][94] Cholbam and CTEXLI - **Sales Performance**: Revenue for Cholbam and CTEXLI has grown to over $160 million, driven by increased awareness and diagnosis efforts [23][24] - **Market Strategy**: Focus on both raising awareness and identifying new patients for these rare conditions [24][26] Brelovitug - **Indication**: Targeting Hepatitis D, a rare and progressive liver disease with significant unmet need [52] - **Clinical Data**: Phase 2 data showed promising results, with a 100% virologic response at 48 weeks [57] - **Enrollment**: Rapid enrollment in registration studies indicates strong interest and potential for success [58] Volixibat - **Indications**: Targeting primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) [78][87] - **Unique Approach**: Using pruritus as a primary endpoint for PSC, which has no approved therapies, represents a novel strategy [78][79] - **Market Potential**: Approximately 30,000 PSC patients in the U.S., with two-thirds experiencing pruritus, indicating a substantial launch population [81][83] Strategic Focus and Future Outlook - **Investment Strategy**: The company aims to balance investments in pipeline development while maintaining a positive cash flow position [98] - **Market Position**: Mirum expects to have a competitive edge in the PSC market due to the lack of approved therapies, allowing for a strong market presence for several years [96][94] - **Long-term Vision**: The company is focused on building value through new medicines and disciplined business development efforts [98][99] Conclusion - Mirum Pharmaceuticals is positioned for significant growth with a robust pipeline and strong commercial performance. The focus on rare diseases and innovative treatment approaches, combined with a solid financial outlook, presents a compelling investment opportunity.

Core Insights - Mirum Pharmaceuticals has completed enrollment in the phase III AZURE-1 study and screening in the AZURE-4 study for its candidate brelovitug, targeting chronic hepatitis delta virus (HDV) [1][5] - The company anticipates reporting top-line 24-week data from both studies in the second half of 2026, which will support a biologics license application (BLA) submission in 2027 [2][5] - Following the announcement, Mirum's shares fell by 5.6%, although the stock has increased by 11.2% year-to-date, outperforming the industry average of 8.1% [2] Study and Drug Development - The AZURE-1 and AZURE-4 studies are assessing a composite endpoint of virologic response and ALT normalization at 24 weeks, aligning with FDA guidelines for accelerated approval [6] - Brelovitug, a fully human monoclonal antibody, was added to Mirum's pipeline through the acquisition of Bluejay Therapeutics in January 2026, enhancing the company's focus on severe liver diseases [3] Financial Performance - Mirum's lead product, Livmarli, generated net sales of $360 million in 2025, reflecting a year-over-year increase of 68.8%, and is a significant revenue driver for the company [8] - Sales of bile acid products, including Livmarli, increased by 31% year-over-year to $161.3 million in 2025 [8] Market Position - Mirum currently holds a Zacks Rank of 3 (Hold), with other biotech stocks like ANI Pharmaceuticals, ALX Oncology, and Replimune Group rated higher [9]

Core Insights - Mirum Pharmaceuticals (MIRM) reported a loss of 11 cents per share in Q4 2025, missing the Zacks Consensus Estimate of earnings of 2 cents, but improved from a loss of 49 cents per share in the same quarter last year [1][10] - Revenues for Q4 totaled $148.9 million, representing a 50.5% year-over-year increase, surpassing the Zacks Consensus Estimate of $141 million, driven by strong sales of Livmarli and newly acquired bile acid medicines [2][8] Financial Performance - The company recorded no license and other revenues in the year-ago quarter, while research and development expenses rose by 16.1% year-over-year to $51.1 million [6] - Selling, general and administrative expenses increased by 30.5% to $74.1 million compared to the previous year [9] - For the full year 2025, Mirum generated revenues of $521.3 million, up from $336.9 million in 2024, with a loss of 47 cents per share, an improvement from a loss of $1.85 in the prior year [10] Product and Pipeline Updates - Livmarli is approved for treating cholestatic pruritus in patients with Alagille syndrome and certain patients with progressive familial intrahepatic cholestasis [3] - A new tablet formulation of Livmarli was launched in the U.S. in June 2025, aimed at providing convenience for older patients [4] - Mirum acquired Travere Therapeutics' bile acid products in August 2023, adding Cholbam and Ctexli to its portfolio [4] - The company expects worldwide net product sales of approximately $630-$650 million in 2026 and aims to achieve positive cash flow in 2027 [11] Clinical Trials and Research - Mirum is conducting a phase III EXPAND study for Livmarli to treat pruritus in rare cholestatic conditions, with enrollment expected to complete in the first half of 2026 [12] - The lead pipeline candidate, volixibat, is being evaluated in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with top-line data expected in 2026 [13] - The company initiated the phase II BLOOM study for MRM-3379, a PDE4D inhibitor for Fragile X syndrome, and completed the acquisition of Bluejay Therapeutics, adding brelovitug to its pipeline [14] Stock Performance - Mirum's shares have increased by 45.5% over the past six months, outperforming the industry average rise of 23% [5]

Financial Data and Key Metrics Changes - In 2025, the company achieved $521 million in net product sales, a 55% increase from $336 million in 2024 [5][14] - The fourth quarter of 2025 saw net product sales of $149 million, compared to $99 million in the same quarter of the previous year [14] - The company ended 2025 with $391 million in cash equivalents, up from $293 million at the end of 2024 [15] Business Line Data and Key Metrics Changes - LIVMARLI net product sales were $245 million in the U.S. and $115 million internationally, with bile acid medicines contributing an additional $161 million [5] - The commercial cash contribution margin in 2025 was approximately 55%, a significant increase from the prior year [15] Market Data and Key Metrics Changes - The company expects net product sales for 2026 to be between $630 million and $650 million, indicating continued growth [6] - The company anticipates a return to positive cash flow in 2027, following increased R&D expenses in 2026 [16] Company Strategy and Development Direction - The company is focused on advancing its pipeline with multiple clinical and regulatory milestones, including the approval of Ctexli for CTX and a tablet formulation of LIVMARLI [6][7] - The addition of the phase III brelovitug program for chronic hepatitis delta virus aligns with the company's strategy to address significant unmet needs in rare diseases [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026, highlighting a strong commercial business and a robust pipeline with four potentially pivotal readouts expected in the next 18 months [17] - The company is committed to disciplined execution and delivering impactful medicines for patients with rare diseases [9][17] Other Important Information - The company completed two private placements concurrent with the closing of the Bluejay acquisition, generating gross proceeds of $268.5 million [15] - The company is on track to report top-line data from the volixibat VISTA study in PSC in the second quarter of 2026 [10][11] Q&A Session Summary Question: Volixibat pricing strategy - Management indicated that pricing considerations for volixibat will be based on data closer to launch, noting its unique positioning due to the lack of approved medicines for PSC [19][20] Question: Risk factors in PSC trial - Management acknowledged the episodic nature of pruritus in PSC patients and emphasized the study design's focus on enrolling patients with persistent pruritus to limit variability [25][28] Question: Similarities between VISTA and VANTAGE study designs - Management highlighted commonalities in studying cholestatic pruritus and confirmed that patients with moderate to severe pruritus will be selected for both studies [35][36] Question: FDA interactions regarding safety database for volixibat - Management confirmed that the current VISTA study has a sufficient safety database and plans to interact with the FDA regarding the submission plan after top-line data [40] Question: Market for hepatitis delta virus (HDV) - Management noted the evolving landscape for HDV treatments and expressed optimism about brelovitug's potential as a best-in-class option [70][71] Question: R&D spending increase for HDV studies - Management anticipates a $150 million increase in R&D spending related to the brelovitug program, with significant investments in CMC [72]

Financial Data and Key Metrics Changes - In 2025, the company achieved $521 million in net product sales, a 55% increase from $336 million in 2024, exceeding the upper end of guidance [5][14] - The total net product sales for Q4 2025 was $149 million, compared to $99 million in Q4 2024 [14] - The commercial cash contribution margin in 2025 was approximately 55%, significantly up from the previous year [15] Business Line Data and Key Metrics Changes - LIVMARLI net product sales were $245 million in the U.S. and $115 million internationally, with bile acid medicines contributing an additional $161 million [5] - The company expects net product sales for 2026 to be between $630 million and $650 million, indicating continued growth [6] Market Data and Key Metrics Changes - The company is seeing strong demand in international markets, particularly for LIVMARLI and its bile acid medicines [5] - The integration of the Bluejay acquisition has progressed smoothly, enhancing the company's operational capabilities [8] Company Strategy and Development Direction - The company is focused on advancing its pipeline with significant clinical and regulatory milestones, including the approval of CTEXLI and the enrollment completion of the VISTAS study for volixibat [6][7] - The addition of the phase III brelovitug program for chronic hepatitis delta virus aligns with the company's strategy to address serious rare diseases [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026, highlighting a pivotal year with multiple potential registrational readouts expected [6][17] - The company anticipates a return to positive cash flow in 2027, supported by disciplined spending and a strong balance sheet [16] Other Important Information - The company ended 2025 with $391 million in cash equivalents, up from $293 million at the end of 2024 [15] - R&D expenses are expected to increase in 2026 due to investments in the brelovitug clinical program and preparations for BLA submission [16] Q&A Session Summary Question: Regarding volixibat's commercial opportunity and pricing strategy - Management indicated that pricing decisions will be made closer to launch, considering the unique positioning of volixibat in the market [19][20] Question: Concerns about pruritus variability in PSC patients - Management acknowledged the episodic nature of pruritus in PSC and emphasized careful patient selection and monitoring in the study design [25][28] Question: Differences between VISTAS and VANTAGE study designs - Management highlighted the commonality in studying cholestatic pruritus while noting the differences in disease etiology between PSC and PBC [33][35] Question: FDA interactions regarding safety database requirements for volixibat - Management confirmed that the current VISTAS study has a sufficient safety database and plans to interact with the FDA post-top-line data [40] Question: Market expectations for HDV and R&D spending - Management discussed the evolving treatment landscape for HDV and anticipated a $150 million increase in R&D spend related to brelovitug [70][72]

Financial Data and Key Metrics Changes - In 2025, the company achieved $521 million in net product sales, a 55% increase from $336 million in 2024, exceeding guidance [4][13] - The total operating expense for 2025 was $543 million, which included R&D expenses of $186 million and SG&A expenses of $257 million [13][14] - The commercial cash contribution margin improved to approximately 55% in 2025, up from the previous year [14] Business Line Data and Key Metrics Changes - LIVMARLI net product sales were $245 million in the U.S. and $115 million internationally, contributing significantly to the overall sales [4] - The bile acid medicines contributed an additional $161 million to the total sales [4] Market Data and Key Metrics Changes - The company expects net product sales for 2026 to be between $630 million and $650 million, indicating continued growth [5] - The company is entering 2026 with a strong pipeline, including four potentially registrational clinical readouts expected over the next 18 months [8] Company Strategy and Development Direction - The company is focused on disciplined execution and growth, with a strong emphasis on advancing its pipeline through clinical and regulatory milestones [5][6] - The addition of brelovitug for chronic hepatitis delta virus is seen as a strategic fit, enhancing the company's portfolio and potential revenue [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for 2026, highlighting the strong performance of the commercial business and the robust pipeline [16] - The company anticipates a return to positive cash flow in 2027, supported by disciplined spending and a strong balance sheet [15] Other Important Information - The company completed two private placements generating gross proceeds of $268.5 million, which will support the acquisition and operational needs [14] - The company has received Fast Track designation from the FDA for MRM-3379 in Fragile X syndrome, indicating its potential to address significant unmet needs [12] Q&A Session Summary Question: Pricing strategy for volixibat - Management indicated that pricing considerations for volixibat will be based on data and market positioning, noting the unique opportunity in the absence of approved therapies for PSC [18][19] Question: Variability in pruritus in PSC patients - Management acknowledged the episodic nature of pruritus in PSC and emphasized the study design's focus on enrolling patients with persistent pruritus to ensure relevant data [23][27] Question: Similarities and differences in study designs for PSC - Management highlighted the commonality in studying cholestatic pruritus across different conditions, with a focus on ensuring that patients with moderate to severe pruritus are enrolled [32][34] Question: FDA interactions regarding safety database for volixibat - Management confirmed that the current study has a sufficient safety database and plans to interact with the FDA regarding submission plans after top-line data is available [38] Question: Market potential for HDV - Management discussed the evolving landscape for HDV treatments and the potential for brelovitug to set a new standard in response rates and safety profiles [68] Question: R&D spending increase for HDV studies - Management anticipates a $150 million increase in R&D spending related to brelovitug, with significant investments in manufacturing and clinical studies [70]

Core Viewpoint - Mirum Pharmaceuticals is positioned for significant growth, with its share price having more than doubled in the past year and expectations for further increases in 2026 due to key developments in its pipeline and financial performance [1]. Financial Performance - Mirum achieved positive cash flow from operations in 2025, marking a significant milestone for the company [2]. - Net product sales for Livmarli increased by 69% year over year in 2025, reaching $359 million, while sales for Cholbam and Ctexli rose by 31% to $161 million. The company anticipates overall revenue guidance of $630 million to $650 million for the current year [5]. Regulatory Approvals - The company received two FDA approvals in the previous year: Ctexli for treating cerebrotendinous xanthomatosis and a tablet formulation of Livmarli for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis [3]. Pipeline Developments - On January 26, 2026, Mirum completed the acquisition of Bluejay Therapeutics, adding brelovitug to its pipeline, which targets chronic hepatitis delta virus, a rare liver disease with no current approved treatment in the U.S. [4]. - The company is expecting results from a Phase 2B clinical study of volixibat for primary sclerosing cholangitis in the second quarter of 2026, with plans to file for accelerated approval in the second half of the year [6]. - Results from a Phase 3 study of brelovitug for HDV treatment are anticipated in the latter half of 2026, with potential filing for approval in early 2027 if results are positive [8]. - The timing of the Phase 3 study of Livmarli for pruritus in rare cholestatic conditions has been accelerated, with enrollment expected to complete in the first half of 2026 and topline data to be reported by year-end [9].

Core Insights - Mirum Pharmaceuticals (MIRM) shares increased by 7.1% following the announcement of strong preliminary results for Q4 and full-year 2025, which boosted investor confidence [1][6] Financial Performance - Preliminary net product sales for Mirum in 2025 were approximately $520 million, exceeding the management's guidance of $500-$510 million provided in November 2025 [2][6] - Estimated net product sales for Livmarli were around $359 million for 2025, while Cholbam and Ctexli contributed approximately $161 million [4] - For Q4 2025, estimated net product sales were about $149 million, including $106 million from Livmarli and around $43 million from Cholbam and Ctexli [5] 2026 Sales Outlook - Mirum forecasts net product sales of approximately $630-$650 million for 2026 [6][7] - The company is conducting a phase III study for Livmarli aimed at treating pruritus in rare cholestatic conditions, with enrollment expected to complete in the first half of 2026 [7] Pipeline Developments - Mirum's lead pipeline candidate, volixibat, is under evaluation in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with top-line data from the VISTAS study anticipated in Q2 2026 [8] - A definitive agreement to acquire Bluejay Therapeutics was announced in December 2025, which will enhance Mirum's portfolio in rare liver diseases [9] - A phase II study has been initiated for MRM-3379, a PDE4D inhibitor targeting Fragile X syndrome [10]

Core Viewpoint - Newsmax, despite having over 50 million regular viewers in the U.S., faces significant competition and challenges in the market, particularly from larger players like Fox Corp, and is predicted to underperform compared to other stocks in the next five years [1][2]. Group 1: Newsmax Overview - Newsmax has a market capitalization of approximately $1.1 billion and has recently expanded into Europe and the Middle East, which may increase its audience [1][2]. - The company reported a net loss of $4.1 million in the third quarter of 2025, indicating ongoing profitability challenges [7]. Group 2: Competitor Analysis - Fox Corp - Fox Corp, Newsmax's largest competitor, has a market cap of nearly $31 billion, significantly larger than Newsmax's [4]. - In the latest quarter, Fox reported a profit of $690 million, while Newsmax's revenue growth is in low single-digit percentages [7]. - Fox's shares have a price-to-sales ratio of 1.8, which is more attractive compared to Newsmax's forward sales multiple of 6 [7]. Group 3: Competitor Analysis - Mirum Pharmaceuticals - Mirum Pharmaceuticals has a market cap of around $4 billion and reported a revenue increase of 47% year-over-year in the third quarter, driven by its liver disease drug Livmarli [8][9]. - The company is optimistic about its pipeline, including potential blockbuster drugs and plans to acquire Bluejay Therapeutics, which could enhance its portfolio [11][12]. Group 4: Competitor Analysis - The Trade Desk - The Trade Desk, a leading advertising technology company, has a market cap of $19 billion and is expected to outperform Newsmax in the long term [13][15]. - The Trade Desk's growth opportunities are bolstered by the rise of ad-supported connected TV and international market expansion [15].